Details of the Drug

General Information of Drug (ID: DM31VNC)

Drug Name
DS-8895
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Drug Type
Antibody
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 172.57
Logarithm of the Partition Coefficient (xlogp) 2
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
Chemical Identifiers
Formula
C6H5ClN2O2
IUPAC Name
5-chloro-3-methyl-2-nitropyridine
Canonical SMILES
CC1=CC(=CN=C1[N+](=O)[O-])Cl
InChI
InChI=1S/C6H5ClN2O2/c1-4-2-5(7)3-8-6(4)9(10)11/h2-3H,1H3
InChIKey
JQKDQMHAQKONAB-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
21894761
TTD ID
D03YBJ

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ephrin type-A receptor 2 (EPHA2) TTRJB2G EPHA2_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02252211) Safety and Bio-Imaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Daiichi Sankyo.